대체: 거래 업데이트
Viohalco-Hellenic 구리 및 알루미늄 산업 SA
€0.00
16:00 25/11/14
The following amendments have been made to the 'Trading Update' announcement released on 21 March 2024 at 07.00 under RNS No 7016H.
The announcement did not include the below footnote:
1Market expectations for FY24 Revenue as at the date of this announcement are £88.7m.
No other changes have been made.
The full text of the amended announcement is set out below.
ECO 동물 건강 그룹 plc
("ECO" 또는 "회사")
거래 업데이트
Trading in-line with market expectations
ECO 동물 건강 그룹 PLC(AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, today announces an update on trading and business progress for the year ending 31 March 2024.
Strong trading from health products globally
Revenue for the fourth quarter and second half of the year ending 31 March 2024, was in line with expectations, driven by continued strong performance of Aivlosin®, the Company's patented antimicrobial used under veterinary prescription for the treatment of economically important respiratory and gastrointestinal diseases in pigs and poultry.
Sustained demand continues in key territories despite economic headwinds experienced by pig producers in certain countries.
The Board expects that revenue for the full year ending 31 March 2024, will be in-line with market expectations1. The Board intends to provide a trading update towards the end of April commenting further on the margin and profit performance for the full year ending 31 March 2024.
R&D - broad portfolio will drive value
ECO continues to invest in developing its R&D pipeline to create a new growth engine, focusing in particular on its late stage Mycoplasma vaccines for poultry and vaccines for swine. ECO recently announced that it had received trademark approval for the ECOVAXXIN® family across the EU, USA and the UK, providing brand protection for a range of vaccine products supporting ECO's plan for multiple product launches and sales growth in key territories expecting to start in 2025 and continuing over the next decade.
Governance - bolstering animal health experience
On 12 February 2024, ECO announced that it had strengthened its Board of Directors with the appointment of Dr. Joachim Hasenmaier as a Non-Executive Director. Dr Hasenmaier brings a wealth of experience, having spent more than two decades in the international animal health industry, ultimately leading one of the largest companies and will support the Company with strategic oversight and governance.
David Hallas, Chief Executive Officer of ECO Animal Health Group plc, commented: "I am pleased to be able to confirm that ECO is on track to meet its full year revenue growth expectations.
"While supported by the growth of Aivlosin®, which continues to take market share from more established products, the Company is making good headway building an R&D engine by creating a pipeline of new vaccines and exciting preventatives for the future and focusing the business on its competitive strengths. While the economic environment requires vigilance, we remain cautiously optimistic.
"Meanwhile, as approved at a General Meeting this week, the Company will begin to purchase shares in the market. This has been facilitated by the use of some of the proceeds from recent property disposals to purchase stock at an attractive price. The Board is confident in the shareholder value creation story at ECO and excited about the Company's future prospects."
1Market expectations for FY24 Revenue as at the date of this announcement are £88.7m.
-Ends-
자세한 내용은 문의하시기 바랍니다 :
|
ECO 동물 건강 정보
ECO Animal Health는 동물 건강 분야의 세계적 선두 기업으로, 돼지와 가금류용 항생제와 백신 분야의 전문 지식을 바탕으로 전 세계적으로 브랜드 동물용 의약품을 개발 및 마케팅하고 있습니다. 우리는 성숙한 독점 R&D 파이프라인을 보유하고 있습니다.
영국에 본사를 두고 R&D 및 제조를 포함한 글로벌 사무소를 두고 있으며 70개국 이상에서 마케팅 승인을 받았으며 전 세계적으로 200명 이상의 직원을 고용하고 있습니다.
당사의 주요 제품인 Aivlosin®은 돼지와 가금류의 호흡기 및 장 질환 모두에 효과적인 독점 특허 약물입니다.
자세한 내용을 보려면 여기를 클릭하세요: https://ecoanimalhealth.com
RNS는 귀하의 IP 주소를 사용하여 약관 준수 여부를 확인하고, 귀하가 이 커뮤니케이션에 포함된 정보를 사용하는 방식을 분석하고, 그러한 분석을 익명으로 다른 사람과 상용 서비스의 일부로 공유할 수 있습니다. RNS와 런던 증권 거래소가 귀하가 제공한 개인 데이터를 사용하는 방법에 대한 자세한 내용은 개인 정보 보호 정책을 참조하십시오.